Skip to main content

Table 2 Memorial Sloan Kettering Regression Schema

From: Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management

 

Complete Response

Near Complete Response

Incomplete Response

Endoscopy

Flat, white scar Telangiectasia No ulcer No nodularity

Irregular mucosa Small mucosal nodules or minor mucosal abnormality Superficial ulceration Mild persisting erythema of the scar

Visible tumor

Digital Rectal Exam

Normal

Smooth induration or minor mucosal abnormalities

Palpable tumor nodules

MRI-T2W

Only dark T2 signal, no intermediate T2 signal

Mostly dark T2 signal, some remaining intermediate signal

More intermediate than dark T2 signal, no T2 scar

AND

AND/OR

AND/OR

No visible lymph nodes

Partial regression of lymph nodes

No regression of lymph nodes

MRI-DW

No visible tumor on B800-B1000 signal

Significant regression of signal on B800-B1000

Insignificant regression of signal on B800-B1000

AND/OR

AND/OR

AND/OR

Lack of or low signal on ADC map Uniform, linear signal in wall above tumor is ok

Minimal or low residual signal on ADC map

Obvious low signal on ADC map